Atopic Dermatitis

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the marketing authorization of Ebglyss for atopic dermatitis in patients aged 12 years and older, according to an Almirall press release.

Atopic dermatitis is an inflammatory skin disease that affects a significant population worldwide. According to the American Academy of Dermatology, it occurs most frequently in children but also impacts as many as 16.5 million adults.

In honor of World Atopic Eczema Day, Almirall announced the launch of its atopic dermatitis awareness campaign, “Moving aheAD,” according to a company press release.

Arcutis Biotherapeutics has submitted a supplemental new drug application to the FDA for roflumilast cream 0.15% for mild to moderate atopic dermatitis treatment in adults and children aged 6 years and older, according to a press release.

Arcutis Biotherapeutics announced interim results of its phase 3, long-term extension trial of roflumilast cream 0.15% for the treatment of atopic dermatitis in adults and children aged 6 years and older, according to a press release.

Children and adults with atopic dermatitis are at an increased risk for inflammatory bowel disease, ulcerative colitis and Chron’s disease, according to a study.

Children and adolescents with atopic dermatitis treated with long-term dupilumab showed positive results and acceptable safety, according to a meta-analysis of multiple studies.

Infants with immature gut microbiota faced greater risks for developing atopic dermatitis, asthma, food allergy and allergic rhinitis by age 5 years, according to a study published in Nature Communications.

The POCN has launched its Atopic Dermatitis Center of Excellence, a free online resource center for nurse practitioners and physician associates working in the atopic dermatitis field, according to a press release.

Greater atopic dermatitis severity correlated with greater disease burden in children and adolescents in Japan, according to a study.